Treating Flavivirus Infections with Amodiaquine and Derivatives Thereof

Quick Links

Disclose Your Invention
MTA/CDA Assistance
Technologies for Licensing
Industry Collaboration Opportunities
Research and Clinical Trials
Education Links
Office of Sponsored Research

Categories: “Viruses, Chronic & Infectious Diseases”

Reference #: 2014-026

OTC Contact: Tracy L. Bruehs, M.S., J.D., Associate Director (Directory Information | Send a Message)

Description

Despite the increase in incidence and seriousness of flavivirus infections such as Dengue and West Nile Virus, there remain no available treatment strategies to manage or prevent the disease. Utilizing a high throughput screening method to identify inhibitors of the Dengue Virus Protease, Georgetown researchers have identified the FDA-approved antimalarial compound amodiaquine as a potent inhibitor of Dengue Virus Protease. Further work has demonstrated that additional amodiaquine derivatives are candidate anti-flavivirus thereapeutics. The repurposing of these compounds offers regulatory advantages due to their established safety in humans, representing an opportunity to treat a neglected disease with an established drug.

Advantages

Stage of Development

Patent Status

Inventor

Radakrishnan Padmanabhan